000118015 001__ 118015 000118015 005__ 20230519145458.0 000118015 0247_ $$2doi$$a10.1038/s41598-021-98659-5 000118015 0248_ $$2sideral$$a126052 000118015 037__ $$aART-2021-126052 000118015 041__ $$aeng 000118015 100__ $$aDi Mambro, T. 000118015 245__ $$aA new humanized antibody is effective against pathogenic fungi in vitro 000118015 260__ $$c2021 000118015 5060_ $$aAccess copy available to the general public$$fUnrestricted 000118015 5203_ $$aInvasive fungal infections mainly affect patients undergoing transplantation, surgery, neoplastic disease, immunocompromised subjects and premature infants, and cause over 1.5 million deaths every year. The most common fungi isolated in invasive diseases are Candida spp., Cryptococcus spp., and Aspergillus spp. and even if four classes of antifungals are available (Azoles, Echinocandins, Polyenes and Pyrimidine analogues), the side effects of drugs and fungal acquired and innate resistance represent the major hurdles to be overcome. Monoclonal antibodies are powerful tools currently used as diagnostic and therapeutic agents in different clinical contexts but not yet developed for the treatment of invasive fungal infections. In this paper we report the development of the first humanized monoclonal antibody specific for beta-1, 3 glucans, a vital component of several pathogenic fungi. H5K1 has been tested on C. auris, one of the most urgent threats and resulted efficient both alone and in combination with Caspofungin and Amphotericin B showing an enhancement effect. Our results support further preclinical and clinical developments for the use of H5K1 in the treatment of patients in need. 000118015 536__ $$9info:eu-repo/grantAgreement/ES/DGA/E30-17R$$9info:eu-repo/grantAgreement/ES/DGA/E30-20R$$9info:eu-repo/grantAgreement/ES/MINECO-FEDER/FIS2017-87519-P 000118015 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000118015 590__ $$a4.997$$b2021 000118015 592__ $$a1.005$$b2021 000118015 591__ $$aMULTIDISCIPLINARY SCIENCES$$b19 / 74 = 0.257$$c2021$$dQ2$$eT1 000118015 593__ $$aMultidisciplinary$$c2021$$dQ1 000118015 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000118015 700__ $$aVanzolini, T. 000118015 700__ $$0(orcid)0000-0002-5833-8798$$aBruscolini, P.$$uUniversidad de Zaragoza 000118015 700__ $$0(orcid)0000-0001-8425-7345$$aPerez-Gaviro, S.$$uUniversidad de Zaragoza 000118015 700__ $$aMarra, E. 000118015 700__ $$aRoscilli, G. 000118015 700__ $$aBianchi, M. 000118015 700__ $$aFraternale, A. 000118015 700__ $$aSchiavano, G.F. 000118015 700__ $$aCanonico, B. 000118015 700__ $$aMagnani, M. 000118015 7102_ $$12004$$2405$$aUniversidad de Zaragoza$$bDpto. Física Teórica$$cÁrea Física Teórica 000118015 773__ $$g11, 1 (2021), 19500 [17 pp.]$$pSci. rep. (Nat. Publ. Group)$$tScientific reports (Nature Publishing Group)$$x2045-2322 000118015 8564_ $$s3730934$$uhttps://zaguan.unizar.es/record/118015/files/texto_completo.pdf$$yVersión publicada 000118015 8564_ $$s2687998$$uhttps://zaguan.unizar.es/record/118015/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000118015 909CO $$ooai:zaguan.unizar.es:118015$$particulos$$pdriver 000118015 951__ $$a2023-05-18-14:53:32 000118015 980__ $$aARTICLE